TMCnet News
Aura Biosciences Strengthens Leadership Team with Addition of Cadmus Rich, M.D., as Chief Medical OfficerAura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, today announced that Cadmus Rich, M.D., has joined the company's leadership team as Chief Medical Officer. In this role, he will oversee all clinical research and development activities. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211005117/en/ Aura Biosciences Strengthens Leadership Team with Addition of Cadmus Rich, M.D., as Chief Medical Officer (Photo: Business Wire) "We welcome Cadmus to our team during a pivotal time at Aura," said Elisabet de los Pinos, Ph.D., founder and CEO of Aura. "As Chief Medical Officer, Cadmus will play an instrumental role as we continue to advance our Phase 1b/2 clinical trial of light-activated AU-011, following release of positive interim safety data last month. We look forward to drawing on his extensive expertise leading product development and commercialization initiatives in ophthalmology." Dr. Rich joins the company from Inotek Pharmaceuticals, where he was Vice President, Medical Affairs and Clinical Development, responsible for development of therapies to treat glaucoma and other serious eye diseases. Prior to Inotek, Dr. Rich held key leadership roles at Alcon, most recently as a Therapeutic Unit Head leading the intraocular lenses team and prior to this, as Global Head of Pharmaceutical Clinical Trial Management. At Alcon, he managed many development programs and clinical trials; therapeutic and device submissions; and approvals for six drugs and five devices ina number of international markets. Before that, he established a new center of excellence in ophthalmology at Quintiles Transnational (now IQVIA), the world's largest contract research organization. Dr. Rich earned a bachelor's degree in psychology from Case Western Reserve University; a Doctor of Medicine from the University of North Carolina (UNC) School of Medicine, Chapel Hill; and a Master of Business Administration from Regis University. He completed his ophthalmology residency at the UNC Department of Ophthalmology, Chapel Hill and additionally, is a Certified Physician Executive. He serves on the national board of directors of Prevent Blindness, a volunteer eye health and safety organization dedicated to fighting blindness and saving sight. "I'm pleased to help lead the important work that Aura is advancing in ocular melanoma, which has no FDA-approved, targeted therapies," said Dr. Rich. "In partnership with our global network of ocular oncology experts, we are striving to provide a novel option for early treatment intervention of this rare disease." Aura also announced today that Alison Lawton has resigned from her role as Chief Operating Officer to pursue other opportunities. She will remain an advisor to Aura.
About ocular melanoma
About light-activated AU-011
About Aura Biosciences View source version on businesswire.com: http://www.businesswire.com/news/home/20171211005117/en/ |